Product image of Mibg (123i) Curium Netherlands (Iodine (123i) Iobenguane) supplied by GNH India

Mibg (123i) Curium Netherlands

Active Ingredient:
Iodine (123i) Iobenguane
Origin:
EU

Mibg (123i) Curium Netherlands (Iodine (123i) Iobenguane)

Iobenguane I-123, the active ingredient in Mibg (123i) Curium Netherlands, is a radiopharmaceutical presented as an injectable solution for intravenous use. It enables visualization of sympathetic nerve activity for cardiac and neuroblastoma imaging in patients undergoing nuclear medicine studies.

GNH India supplies Mibg (123i) Curium Netherlands as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and nuclear medicine clinics worldwide.

Manufacturer / TM Owner

Curium Netherlands B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mibg (123i) Curium is used in nuclear medicine to assess sympathetic nerve function in specific disease contexts.

  • Cardiac sympathetic innervation imaging: visualizes myocardial sympathetic nerve distribution to aid diagnosis and risk assessment.
  • Heart failure risk stratification: provides functional data on cardiac sympathetic activity to help guide therapeutic decisions.
  • Neuroblastoma imaging: detects neuroblastoma lesions by targeting the norepinephrine transporter in tumor cells.

How It Works

  • Iobenguane I-123 is taken up by adrenergic nerve terminals via the norepinephrine transporter (NET). Once internalized, the radiolabel emits gamma photons that are captured by SPECT cameras, allowing clinicians to map sympathetic innervation in the heart or locate neuroblastoma tissue that expresses NET, thereby providing functional imaging information.

Side Effects

Adverse reactions may occur following intravenous administration of Iobenguane I-123.

Common Side Effects

  • Nausea: mild and transient.
  • Headache: occasional during or after injection.
  • Flushing: brief skin reddening.
  • Injection site pain: mild discomfort at the venipuncture site.
  • Transient hypertension: short‑lived rise in blood pressure.
  • Dizziness: mild light‑headedness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Severe hypotension: marked drop in blood pressure.
  • Radiation‑induced tissue injury: localized damage at high exposure sites.
  • Arrhythmia: abnormal heart rhythm.
  • Severe skin reaction: extensive rash or urticaria.
  • Thyroid dysfunction: abnormal thyroid hormone levels due to iodine exposure.

Precautions & Warnings

Prior to use, clinicians should evaluate patient‑specific factors and follow safety guidelines.

  • Pregnancy: avoid unless clearly needed, as fetal radiation exposure is possible.
  • Breastfeeding: discontinue nursing for an appropriate interval after administration.
  • Radiation safety: limit staff exposure and follow local radiation protection protocols.
  • Renal function: assess because the tracer is cleared renally.
  • Thyroid blocking: consider iodine blockade in patients at risk for thyroid uptake.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Iobenguane I-123 may interact with other agents that affect norepinephrine pathways or iodine handling.

Major Interactions (Avoid)

  • Sympathomimetic drugs (e.g., epinephrine): compete for NET uptake and may reduce image quality.
  • Iodine‑containing contrast agents: can interfere with tracer distribution and imaging interpretation.
  • Thyroid hormone therapy: may alter iodine metabolism and affect tracer uptake.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may modify sympathetic activity and influence tracer accumulation.
  • Calcium channel blockers: could affect cardiac perfusion and imaging results.
  • Diuretics: may change renal clearance of the radiotracer.

Frequently Asked Questions

Mibg (123i) Curium is a radiopharmaceutical used in nuclear medicine to image sympathetic nerve activity. It is primarily employed for cardiac sympathetic innervation imaging to assess heart disease and for detecting neuroblastoma tumors by visualizing norepinephrine transporter expression.

Iobenguane I-123 mimics norepinephrine and is taken up by adrenergic nerve terminals via the norepinephrine transporter. The iodine‑123 label emits gamma radiation, which is captured by SPECT cameras, producing detailed images of sympathetic innervation in the heart or neuroblastoma tissue.

The administered activity of Iobenguane I-123 is determined by the prescribing physician or nuclear medicine specialist based on the patient's weight, the imaging protocol, and regulatory guidelines. Exact dosing is individualized and not standardized in public documentation.

Because Iobenguane I-123 involves ionizing radiation, it is generally avoided in pregnancy unless the diagnostic benefit outweighs the risk. Breastfeeding mothers should discontinue nursing for a period recommended by the treating physician to prevent infant radiation exposure.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with agents such as 123I‑MIBG, Iobenguane I-123 offers similar NET targeting but may differ in specific activity, imaging protocols, and regulatory status. Choice of agent depends on local availability, imaging equipment, and the clinical question; both provide valuable information on sympathetic innervation.

The product must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. It should be kept in its original container until use and handled by trained personnel in a radiation‑controlled environment.

Mibg (123i) Curium is administered as a single intravenous injection under sterile conditions. The dose is prepared by a qualified radiopharmacy, and imaging is performed shortly after injection according to the specific nuclear medicine protocol.

Serious risks include severe allergic reactions (anaphylaxis), significant hypotension or hypertension, radiation‑induced tissue injury, arrhythmias, and rare thyroid dysfunction due to iodine exposure. Patients should be monitored closely during and after administration.

Patients with known hypersensitivity to iodine or Iobenguane, those who are pregnant unless absolutely necessary, and individuals with uncontrolled thyroid disorders should avoid the product. Contra‑indications are determined by the prescribing clinician based on medical history.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Iodine (123i) Iobenguane

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT